Anti-CCR7 and -CCL19 monoclonal antibodies enhance HSC and MPC proliferation after HSCT and Aspergillus challenge. Lethally irradiated WT mice reconstituted with 6.0 × 102 HSCs, 1.0 × 104 CMPs, and 1.0 × 104 GMPs from WT mice were given an intraperitoneal injection of 25 μg of anti-CCR7 (A-B), anti-CCL19 (C), or IgG (A-C) every other day for 14 days after HSCT. (A-B) Fourteen days after HSCT and anti-CCR7 treatment, mice were challenged with 2.0 × 106 conidia. Lungs (A) and BM (B) were analyzed 48 hours after infection. (C) The number of cells present in the BM of uninfected HSCT mice treated with anti-CCL19 or -CCL21 (n = 4-5 mice per group, representative of 2 experiments). *P < .05, when comparing anti-CCR7 or -CCL19 and IgG-treated chimeras.
